Punjab, April 13 -- The DOORwaY90 study met its prespecified co-primary endpoints, achieving a best overall response rate (ORR) of 99%WOBURN, Mass., April 13, 2026 /PRNewswire/ -Sirtex Medical ("Sirtex"), a leading manufacturer of interventional oncology and embolization solutions, today announced landmark 12-month results from the DOORwaY90 study, the first pivotal, prospective, multicenter U.S. trial of Y-90 selective internal radiation therapy (SIRT) using partition dosimetry in patients with unresectable hepatocellular carcinoma (HCC). The DOORwaY90 study met its prespecified co-primary endpoints, demonstrating a 90% complete response (CR) rate and a best overall response rate (ORR) of 99%, as assessed by blinded independent central rev...